HLS Therapeutics Inc. (TSE:HLS - Free Report) - Raymond James upped their Q2 2025 EPS estimates for shares of HLS Therapeutics in a research note issued to investors on Monday, May 12th. Raymond James analyst M. Freeman now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.22). The consensus estimate for HLS Therapeutics' current full-year earnings is ($0.12) per share. Raymond James also issued estimates for HLS Therapeutics' Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.28) EPS and FY2027 earnings at ($0.17) EPS.
Separately, Stifel Nicolaus upped their price objective on HLS Therapeutics from C$3.50 to C$4.00 and gave the stock a "hold" rating in a research report on Wednesday, March 26th.
View Our Latest Stock Analysis on HLS
HLS Therapeutics Price Performance
Shares of HLS stock traded down C$0.07 during trading hours on Thursday, reaching C$4.73. The company's stock had a trading volume of 2,406 shares, compared to its average volume of 13,771. HLS Therapeutics has a fifty-two week low of C$3.00 and a fifty-two week high of C$4.98. The firm's 50 day simple moving average is C$4.37 and its 200-day simple moving average is C$4.02. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. The company has a market capitalization of C$105.23 million, a price-to-earnings ratio of -4.74 and a beta of 1.07.
About HLS Therapeutics
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
See Also
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
